Abstract：
UNASSIGNED: This study aims to investigate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in the treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.
UNASSIGNED: This retrospective analysis included 16 patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation between 2016 and 2022. Among them, 8 patients received HBOT in addition to conventional treatment, while the other 8 received only conventional treatment. The clinical efficacy and safety of HBOT were evaluated by comparing the Numeric Rating Scale pain scores and clinical grades of hematuria before and after treatment, reflecting the patients\' urinary pain and hematuria status.
UNASSIGNED: The patients were divided into two groups based on whether they received HBOT. The group that received HBOT (n = 8) had a shorter duration of illness compared to the non-HBOT group (n = 8) (p < 0.05). The time for the NRS to decrease to below 2 was also shorter in the HBOT group. Furthermore, the patients who received HBOT did not experience any significant adverse reactions.
UNASSIGNED: The combination of conventional treatment and hyperbaric oxygen therapy (HBOT) has been shown to improve symptoms such as urinary pain, frequency, urgency, and hematuria in patients with late-onset hemorrhagic cystitis after transplantation. This approach has been proven to be safe and effective.
UNASSIGNED: This retrospective analysis included 16 patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation between 2016 and 2022. Among them, 8 patients received HBOT in addition to conventional treatment, while the other 8 received only conventional treatment. The clinical efficacy and safety of HBOT were evaluated by comparing the Numeric Rating Scale pain scores and clinical grades of hematuria before and after treatment, reflecting the patients\' urinary pain and hematuria status.
UNASSIGNED: The patients were divided into two groups based on whether they received HBOT. The group that received HBOT (n = 8) had a shorter duration of illness compared to the non-HBOT group (n = 8) (p < 0.05). The time for the NRS to decrease to below 2 was also shorter in the HBOT group. Furthermore, the patients who received HBOT did not experience any significant adverse reactions.
UNASSIGNED: The combination of conventional treatment and hyperbaric oxygen therapy (HBOT) has been shown to improve symptoms such as urinary pain, frequency, urgency, and hematuria in patients with late-onset hemorrhagic cystitis after transplantation. This approach has been proven to be safe and effective.
摘要：
■本研究旨在探讨高压氧疗法（HBOT）治疗异基因造血干细胞移植后迟发性出血性膀胱炎的疗效和安全性。
■这项回顾性分析包括2016年至2022年间异基因造血干细胞移植后晚发性出血性膀胱炎的16例患者。其中,8例患者除常规治疗外还接受了HBOT,而另外8人仅接受常规治疗。通过比较治疗前后疼痛数字评定量表评分和血尿临床分级,评价HBOT的临床疗效和安全性,反映患者尿路疼痛和血尿状态。
■根据是否接受HBOT将患者分为两组。与非HBOT组（n=8）相比，接受HBOT组（n=8）的疾病持续时间更短（p<0.05）。HBOT组NRS降至2以下的时间也较短。此外，接受HBOT治疗的患者未出现任何显著不良反应.
■常规治疗和高压氧治疗（HBOT）的结合已被证明可以改善尿痛等症状，频率,紧迫性,移植后晚发性出血性膀胱炎患者的血尿。这种方法已被证明是安全有效的。
■这项回顾性分析包括2016年至2022年间异基因造血干细胞移植后晚发性出血性膀胱炎的16例患者。其中,8例患者除常规治疗外还接受了HBOT,而另外8人仅接受常规治疗。通过比较治疗前后疼痛数字评定量表评分和血尿临床分级,评价HBOT的临床疗效和安全性,反映患者尿路疼痛和血尿状态。
■根据是否接受HBOT将患者分为两组。与非HBOT组（n=8）相比，接受HBOT组（n=8）的疾病持续时间更短（p<0.05）。HBOT组NRS降至2以下的时间也较短。此外，接受HBOT治疗的患者未出现任何显著不良反应.
■常规治疗和高压氧治疗（HBOT）的结合已被证明可以改善尿痛等症状，频率,紧迫性,移植后晚发性出血性膀胱炎患者的血尿。这种方法已被证明是安全有效的。
